China
Africa
Explore chapters and articles related to this topic
Therapeutic Strategies and Future Research
Published in Mark A. Mentzer, Mild Traumatic Brain Injury, 2020
Soon perhaps a treatment for cancer epigenetics will be effected through localized solvent physiology changes that reprogram the cancer cell behaviors. If the triggering mechanism for cancer cell programming is identified and reversed, the basis for a cure or reversal of the condition may be possible. Antiangiogenic agents, epigenetic reprogramming—perhaps even structured water with appropriate solvents changing the ion transport of potassium across cell boundaries—may alter sufficiently the folding of proteins during cancer cell processes. It seems that recent breakthroughs (Medical College of Georgia, 2009; University of Illinois at Urbana-Champaign, 2008) in the understanding of DNA methylation may provide the epigenetic key for screening, prevention, and cure of many or all cancers. Analogous approaches in neuroscience promise breakthroughs as well.
Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors
Published in Expert Review of Anticancer Therapy, 2019
Zhenghui Liu, Yingxue Gao, Xiong Li
A large number of next-generation epigenetic target molecules such as BET inhibitors and Jumonji inhibitors have been developed and tested in clinical trials, along with the identification of a series of epigenetic biomarkers [103,104]. Also, new technologies like the gene-editing CRISPER-CAS9 have been used for accurately repairing gene mutations and epigenetic alterations. Patient-derived tumor xenograft models (PDX) are convenient models for the screening and evaluation of epigenetic drugs. These revolutionary technologies suggest a bright future for effective epigenetic therapies and precision personal medicine [105]. Growing evidence demonstrates that cancer epigenetics are closely and mutually associated with cancer immunology. Future epigenetic therapies could provoke anticancer immune responses, and conversely the activation of anti-tumor immune functions may strengthen the anticancer effects of epigenetic drugs [106]. For example, Azacytidine, a DNMT inhibitor, and Entanostat, a HDAC inhibitor, significantly improved the efficacy of adoptive immunotherapy and immune checkpoint inhibitors [107]. Combination strategies exploiting anticancer immunotherapy and epigenetic drugs have great potential [93,108].
Proteomic approaches for cancer epigenetics research
Published in Expert Review of Proteomics, 2019
Dylan M. Marchione, Benjamin A. Garcia, John Wojcik
Please note, the focus of this review is not on general proteomics (see [27,28]), on the proteomic analysis of histones (see [29–31]) nor on epigenetic mechanisms of cancer (see [1,32,33]). This review examines the specific application of proteomics to cancer epigenetics research. We review the history, highlight important lessons learned via several ‘case reports,’ discuss outstanding issues, and conclude with an outlook regarding the future of this exciting and fruitful area of research.